Assessment of the Effectiveness of Glp-1 Agonists in Non-Alcoholic Fatty Liver Disease Associated With Obesity and Insulin Resistance

To evaluate the effectiveness of GLP-1 agonists for non-alcoholic fatty liver disease in women of different age groups against the background of obesity and insulin resistance.

102 patients with non-alcoholic fatty liver disease at the steatosis stage were examined. The patients were divided into 2 groups: 1st group - main - 47 women of fertile age with non-alcoholic fatty liver disease, 2nd group - comparison - 55 women perimenopausal age with non-alcoholic fatty liver disease. 37 patients of them were practically healthy people and were selected as a control groupTo verify the diagnosis, in addition to general clinical data, we used the results of ultrasound examination of the liver, the determination of liver enzymes in blood serum and lipids. Bioimpedance measurements were performed on all patients to assess body fat (total and visceral fat) and muscle mass.

The examined patients revealed significant changes in the blood lipid spectrum towards an increase in total cholesterol, low-density lipoproteins and triglycerides, and a decrease in the level of high-density lipoproteins. When analyzing bioimpedansometry data, a significant increase in the amount of total and visceral fat was noted, as well as a tendency towards a decrease in muscle mass.

It has been established that the development of NAFLD is statistically significantly associated with an increase in the amount of adipose tissue (total and visceral fat) and a decrease in muscle mass associated with dyslipidemia. An increase in the amount of adipose tissue, including due to visceral fat, and a decrease in muscle mass are considered risk factors for the development of NAFLD.